Diagnostic value of anti-Müllerian hormone combined with androgen-levels in Chinese patients with polycystic ovary syndrome

Figures & data

Table 1. General parameters of 450 PCOS patients and 100 controls.

Characteristics	PCOS (n = 450)	Controls (n = 100)	Statistics	P-value
Age (year)	29.64 ± 4.25	31.269 ± 3.59	1.064^▲	0.074
Weight (kg)	66.756 ± 14.01	57.70 ± 6.86	6.979^▲	<0.001*
BMI (kg/m^2)	25.03 ± 4.98	22.49 ± 2.89	6.938^▲	<0.001*
Waist (cm)	84.91 ± 12.32	78.83 ± 9.74	4.736^▲	<0.001*
Hip (cm)	97.56 ± 10.31	94.21 ± 7.3	3.707^▲	<0.001*
SBP (mmHg)	121 ± 13	118 ± 13	1.646^▲	0.054
DBP (mmHg)	76 ± 11	74 ± 9	1.463^▲	0.100

Values are mean and standard deviation, BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure.

^▲Represents t-test; *represents p < 0.05.

Figure 1. Serum AMH concentrations in PCOS versus the controls. Data were presented as mean standard deviation of the mean. AMH: anti-Müllerian hormone; PCOS: polycystic ovary syndrome.

Table 2. The androgens, AMH and LH/FSH ratio of women in the PCOS and controls group.

Characteristics	PCOS (n = 450)	Controls (n = 100)	Statistics	P-value
AMH (ng/mL)	8.06 ± 4.02	2.93 ± 1.38	12.061^▲	<0.001*
FSH (IU/L)	5.62 ± 1.80	5.47 ± 2.10	0.777^▲	0.420
LH (IU/L)	11.46 ± 7.37	5.00 ± 2.20	14.472^▲	<0.001*
LH/FSH	2.09 ± 1.28	1.08 ± 1.70	11.330^▲	<0.001*
E2 (pg/mL)	51.67 ± 14.72	55.65 ± 15.28	−0.818^▲	0.720
PRL (ng/mL)	12.35(7.3-13.4)	11.9 (8.8-16.7)	−1.664^■	0.011*
P (ng/mL)	0.61 ± 0.22	0.56 ± 0.21	−0.181^▲	0.670
T (pg/mL)	440 ± 290	279 ± 123	10.114^▲	<0.001*
FT (pg/mL)	7.79 ± 6.38	4.05 ± 1.8	10.987^▲	<0.001*
BIOT (pg/mL)	189 ± 119	101 ± 45	12.321^▲	<0.001*
SHBG (nmol/L)	32.9(19.7-51.5)	47.7(30.1-62.6)	−5.911^▲	<0.001*
A2 (ng/mL)	1.83 ± 0.84	1.13 ± 0.46	10.326^▲	<0.001
17-OHP (ng/mL)	1.15 ± 0.21	1.05 ± 0.18	−0.529^▲	0.597
DHEAS (ng/mL)	2516.91(1979.58-3207.37)	1709.36(1469.21-2234.07)	−1.06^■	<0.001*
TSH (mIU/L)	2.30 ± 1.58	2.24 ± 1.3	0.277^▲	0.782
F (nmol/L)	318.2 ± 138.8	286.7 ± 94.7	1.833^▲	0.067

Values are presented as mean ± standard deviation. AMH: anti-Müllerian hormone; FSH: follicle stimulating hormone; LH: luteinizing hormone; LH/FSH: LH FSH ratio; PRL: prolactin; P: progesterone; SHBG: sex hormone binding globulin; FT: Free testosterone; T: Total testosterone; BIOT: bioavailable testosterone; A2: androstenedione; DHEAS: dehydroepiandrosterone sulfate; 17-OHP: 17-hydroxyprogesterone; TSH: Thyroid Stimulating Hormone; F: Cortisol.

^▲Represents t-test; ^■Represents Mann-Whitney U-test; *represents p < 0.05.

Figure 2. (A) Combined curve of AMH with free testosterone. (B) Combined curve of AMH with total testosterone. (C) Combined curve of AMH with BioT. (D) Combined curve of AMH with A2. (E) Diagnostic potential of AMH, total testosterone, free testosterone, BioT and A2 for PCOS estimated using ROC analysis.

Figure 3. Relationship of AMH to FT, SHBG, total testosterone, and LH FSH ratio in PCOS (upper panel) and controls (down panel).

Abbreviation: AMH: anti-Müllerian hormone; PCOS: polycystic ovary syndrome; SHBG: sex hormone binding globulin; FT: free testosterone; T:total testosterone; A2:androstenedione; BIOT: bioavailable testosterone; DHEAS: dehydroepiandrosterone sulfate; 17-OHP: 17hydroxypro-gesterone, LH/FSH: LH FSH ratio.